Connors Investor Services Inc. Has $202,000 Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

Connors Investor Services Inc. reduced its position in OptimizeRx Co. (NASDAQ:OPRX) by 32.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 16,607 shares of the company’s stock after selling 7,893 shares during the period. Connors Investor Services Inc. owned 0.09% of OptimizeRx worth $202,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in OPRX. Millrace Asset Group Inc. acquired a new stake in shares of OptimizeRx in the 4th quarter valued at $1,917,000. G2 Investment Partners Management LLC increased its holdings in OptimizeRx by 26.0% in the fourth quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock valued at $6,699,000 after purchasing an additional 96,646 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in OptimizeRx in the first quarter valued at about $1,053,000. Rice Hall James & Associates LLC increased its holdings in shares of OptimizeRx by 17.3% in the first quarter. Rice Hall James & Associates LLC now owns 401,882 shares of the company’s stock worth $4,883,000 after acquiring an additional 59,141 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of OptimizeRx in the first quarter worth about $542,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price objective on shares of OptimizeRx in a research report on Wednesday, May 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price objective on shares of OptimizeRx in a research report on Monday, April 1st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 price objective on shares of OptimizeRx in a research report on Friday, June 21st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $16.00.

OptimizeRx Stock Up 0.9 %

NASDAQ OPRX traded up $0.09 during trading hours on Monday, hitting $10.11. 34,652 shares of the company traded hands, compared to its average volume of 126,997. The business’s 50-day moving average is $11.11 and its 200-day moving average is $12.45. OptimizeRx Co. has a twelve month low of $6.92 and a twelve month high of $16.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.88 and a current ratio of 2.88. The stock has a market capitalization of $184.71 million, a price-to-earnings ratio of -9.77 and a beta of 1.26.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $18.66 million. During the same period last year, the company posted ($0.34) earnings per share. Sell-side analysts anticipate that OptimizeRx Co. will post -0.42 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.